Neuropathic pain

BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives

Retrieved on: 
Tuesday, June 27, 2023
Patent, CSE, Depression, Anxiety, LSD, DSM-IV codes, Trademark, Pain, Headache, Neuropathic pain, Neuro, IND, Pharmaceutical industry

This U.S. Patent Application is part of a developing international patent portfolio which cover compositions of these derivatives.

Key Points: 
  • This U.S. Patent Application is part of a developing international patent portfolio which cover compositions of these derivatives.
  • BetterLife has developed “BETR-001”, a new 2-bromo-LSD derivative covered by these patent filings.
  • In addition to composition claims, these applications also cover a novel method for making non-hallucinogenic LSD derivatives that does not involve the use of strictly controlled intermediate substances.
  • Dr. Ahmad Doroudian, CEO of BetterLife commented, “2-bromo-LSD was originally thought to be neuro-pharmacologically inactive compared to LSD.

Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (“CHT” or “Territories Distributor”) and Farouk, Maamoun Tamer & Co. (“Master Distributor”) For the Distribution of ZTlido® in the Kingdom of Saudi Arabia

Retrieved on: 
Wednesday, May 31, 2023
Business development, Farooq, PALO, Research, KSA, Trigeminal neuralgia, PHN, CH, Risk, Neuropathic pain, Pain management, OTC, Islam, Therapy, Chronic pain, Pharmaceutical industry, Kingdom

Designated Territories will include Kingdom of Saudi Arabia.

Key Points: 
  • Designated Territories will include Kingdom of Saudi Arabia.
  • ZTlido® is a lidocaine topical system approved for the relief of neuropathic pain associated with post-herpetic neuralgia (PHN).
  • ZTlido® was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period.
  • “This agreement represents another critical milestone towards bringing our innovative non-opioid pain management medicines to people around the world,” said Jaisim Shah, President and Chief Executive Officer of Scilex.

Global Diabetic Neuropathy Market Report 2023: Introduction of Novel Drugs that are Specifically Designed to Treat Neuropathic Pain Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 30, 2023
Diabetes, Pharmaceutical, Health, Diabetic neuropathy, Prevalence, Paresthesia, Hypoesthesia, International Diabetes Federation, USD, Muscle weakness, Incidence, Patient, Neuropathic pain, Growth, RNA interference, System, Nerve, Dietary supplement, Pharmaceutical industry

The "Global Diabetic Neuropathy Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Diabetic Neuropathy Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global diabetic neuropathy market value was USD 4.74 billion in 2022, driven by the increasing prevalence of diabetic patients across the globe.
  • As per the market scenario, the global diabetic neuropathy market is expected to witness substantial growth in the coming years due to the increasing prevalence of diabetes worldwide.
  • Furthermore, the introduction of novel drugs that are specifically designed to treat neuropathic pain is expected to drive market growth.

Nalu Medical, Inc. Announces First Enrollment of COMFORT-2 Peripheral Nerve Stimulation Randomized Controlled Trial

Retrieved on: 
Wednesday, May 31, 2023
Technology, Medical Devices, Surgery, Neurology, Clinical Trials, Nanotechnology, Biotechnology, Physical Therapy, General Health, Health, Ankle, Medicine, Diabetic neuropathy, Additive effect, Shoulder, SCS, American Society of Interventional Pain Physicians, Clinical trial, Trial of the century, Foot, Spinal cord, Nalu, Brain, PNS, Pain, Patient, Clinical study design, Randomized controlled trial, Neuropathic pain, Nerve, Pain management, Spinal cord stimulator, FDA, Chronic pain, Safety, Society, Treatment, Knee, Level 1, Medical device, Nursing, Medical imaging, Pharmaceutical industry, Neuroscience

Nalu Medical, Inc. (“Nalu”) a Carlsbad, California-based company that markets a minimally invasive neurostimulation implant for the management of chronic intractable pain for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications, announces the first patient enrollment in the Clinical Study Of A Micro-Implantable Pulse Generator For the Treatment of Peripheral Neuropathic Pain (COMFORT-2) Peripheral Nerve Stimulation Randomized Controlled Trial.

Key Points: 
  • Nalu Medical, Inc. (“Nalu”) a Carlsbad, California-based company that markets a minimally invasive neurostimulation implant for the management of chronic intractable pain for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications, announces the first patient enrollment in the Clinical Study Of A Micro-Implantable Pulse Generator For the Treatment of Peripheral Neuropathic Pain (COMFORT-2) Peripheral Nerve Stimulation Randomized Controlled Trial.
  • The Nalu PNS system incorporates a battery-free, micro implantable pulse generator (micro-IPG™), powered by an externally worn device (Therapy Disc) housing the battery and controller.
  • Dr. John Hatheway, interventional pain physician at Northwest Pain Care in Spokane, Washington, enrolled the first patient in the COMFORT-2 randomized controlled trial.
  • We are committed to being the leader in PNS clinical data development.”
    This is the second PNS randomized controlled trial sponsored by Nalu Medical.

Algiax Pharmaceuticals Announces Positive Interim Analysis of Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain

Retrieved on: 
Tuesday, May 30, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Diabetic neuropathy, Neuron, Drug development, University, Czech Republic, International Association, Quality of life, Neuropathic pain, Medication, IASP, Dizziness, Patient, GABAA, International Association for the Study of Pain, DRG, Neurology, Data monitoring committee, DMC, Safety, Addiction, Pharmaceutical industry, Pain

Algiax Pharmaceuticals , today provided an update on its ongoing Phase 2a study ( NCT04429919 ) with lead candidate AP-325 in patients with chronic neuropathic pain.

Key Points: 
  • Algiax Pharmaceuticals , today provided an update on its ongoing Phase 2a study ( NCT04429919 ) with lead candidate AP-325 in patients with chronic neuropathic pain.
  • The study is continuing as planned with topline efficacy readouts and a more in-depth safety analysis expected at the conclusion in 2024.
  • Neuropathic pain is a chronic condition that is oftentimes associated with an imbalance in excitatory and inhibitory neuronal signals.
  • In its preclinical evaluation, Aligax’s lead candidate demonstrated dose-dependent, long-lasting efficacy on mechanical and thermal pain reception in models of central neuropathic pain, peripheral neuropathic pain, and diabetic neuropathy.

Tetra Pharm Technologies strengthens management board

Retrieved on: 
Tuesday, May 16, 2023
Tetra, Sclerosis, Communication, Marketing, Head, Overalls, Copenhagen Business School, CMO, Strategic planning, Business administration, Patient, Master of Science, Neuropathic pain, Trade, Niels Brock Copenhagen Business College, CFO, Knowledge, Growth, Tourism, Management, Renewable energy

COPENHAGEN, Denmark, May 16, 2023 /PRNewswire/ -- Tetra Pharm Technologies develops and manufactures pharmaceutical drugs targeting the endocannabinoid system for the treatment of neuropathic pain, sclerosis, and mental health disorders. The expansion of the management board is due to the company's increasing level of activity and ambition.

Key Points: 
  • The Danish biotech company, Tetra Pharm Technologies, is expanding its management board with Mr. Steen Jakobsen as Chief Financial Officer (CFO) and Mr. Jacob Schlundt as Chief Marketing Officer (CMO).
  • "Tetra Pharm Technologies has reached a size that makes it necessary to expand the management board.
  • Steen Jakobsen brings solid experience in strategic planning, finance, and management, and he will take responsibility of the overall finance function at Tetra Pharm Technologies.
  • Tetra Pharm Technologies has recruited Jacob Schlundt from a role as Head of Marketing & Communications at Aon Denmark, and he brings extensive knowledge within marketing, communication, and event planning to strengthen Tetra Pharm Technologies' global position and profile.

Tetra Pharm Technologies strengthens management board

Retrieved on: 
Tuesday, May 16, 2023
Tetra, Sclerosis, Communication, Marketing, Head, Overalls, Copenhagen Business School, CMO, Strategic planning, Business administration, Patient, Master of Science, Neuropathic pain, Trade, Niels Brock Copenhagen Business College, CFO, Knowledge, Growth, Tourism, Management, Renewable energy

COPENHAGEN, Denmark, May 16, 2023 /PRNewswire/ -- Tetra Pharm Technologies develops and manufactures pharmaceutical drugs targeting the endocannabinoid system for the treatment of neuropathic pain, sclerosis, and mental health disorders. The expansion of the management board is due to the company's increasing level of activity and ambition.

Key Points: 
  • The Danish biotech company, Tetra Pharm Technologies, is expanding its management board with Mr. Steen Jakobsen as Chief Financial Officer (CFO) and Mr. Jacob Schlundt as Chief Marketing Officer (CMO).
  • "Tetra Pharm Technologies has reached a size that makes it necessary to expand the management board.
  • Steen Jakobsen brings solid experience in strategic planning, finance, and management, and he will take responsibility of the overall finance function at Tetra Pharm Technologies.
  • Tetra Pharm Technologies has recruited Jacob Schlundt from a role as Head of Marketing & Communications at Aon Denmark, and he brings extensive knowledge within marketing, communication, and event planning to strengthen Tetra Pharm Technologies' global position and profile.

Tetra Pharm Technologies launches first product in Germany

Retrieved on: 
Wednesday, May 3, 2023
Tetra, Sclerosis, Partnership, Pharmacy, PHOENIX, Cannabinoid, Research, Patient, Neuropathic pain, Pharmaceutical industry

COPENHAGEN, Denmark, May 3, 2023 /PRNewswire/ -- Tetra Pharm Technologies develops and manufactures pharmaceutical drugs targeting the endocannabinoid system for the treatment of neuropathic pain, sclerosis and mental health disorders.

Key Points: 
  • The Danish biotech company, Tetra Pharm Technologies, is launching its first product, XATEPA®, on the German market.
  • COPENHAGEN, Denmark, May 3, 2023 /PRNewswire/ -- Tetra Pharm Technologies develops and manufactures pharmaceutical drugs targeting the endocannabinoid system for the treatment of neuropathic pain, sclerosis and mental health disorders.
  • "The launch of our first product represents an important and significant milestone for Tetra Pharm Technologies.
  • Tetra Pharm Technologies has entered into an agreement with PHOENIX Pharma-Einkauf GmbH for the distribution of XATEPA® in Germany.

Tetra Pharm Technologies launches first product in Germany

Retrieved on: 
Wednesday, May 3, 2023
Tetra, Sclerosis, Partnership, Pharmacy, PHOENIX, Cannabinoid, Research, Patient, Neuropathic pain, Pharmaceutical industry

COPENHAGEN, Denmark, May 3, 2023 /PRNewswire/ -- Tetra Pharm Technologies develops and manufactures pharmaceutical drugs targeting the endocannabinoid system for the treatment of neuropathic pain, sclerosis and mental health disorders.

Key Points: 
  • The Danish biotech company, Tetra Pharm Technologies, is launching its first product, XATEPA®, on the German market.
  • COPENHAGEN, Denmark, May 3, 2023 /PRNewswire/ -- Tetra Pharm Technologies develops and manufactures pharmaceutical drugs targeting the endocannabinoid system for the treatment of neuropathic pain, sclerosis and mental health disorders.
  • "The launch of our first product represents an important and significant milestone for Tetra Pharm Technologies.
  • Tetra Pharm Technologies has entered into an agreement with PHOENIX Pharma-Einkauf GmbH for the distribution of XATEPA® in Germany.

Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 2, 2023
Heart failure, NDA, Postherpetic neuralgia, Congress, PHN, Risk, Neuropathic pain, PDUFA, American College, Lexicon Pharmaceuticals, FDA, SGLT, DPN, Pharmaceutical industry, Cardiology

THE WOODLANDS, Texas, May 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023 and provided an update on key corporate milestones.

Key Points: 
  • NDA for Sotagliflozin on Track for May 27th, 2023 PDUFA date
    THE WOODLANDS, Texas, May 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023 and provided an update on key corporate milestones.
  • For the first quarters of 2023 and 2022, net loss included non-cash, stock-based compensation expense of $3.4 million and $2.8 million, respectively.
  • Cash and Investments: As of March 31, 2023, Lexicon had $105.9 million in cash and investments, as compared to $138.4 million as of December 31, 2022.
  • Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update.